AQS.VTSXVHealthcare · Drug Manufacturers - Specialty & Generic

Aequus Pharmaceuticals Inc.

$0.01+0.00%(+$0.00)

TickerSpark Score

55/100

Mixed

Valuation

Profitability

100

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AQS.V research report →

52-Week Range0% of range

Low $0.01

Current $0.01

High $0.04

Companywww.aequuspharma.ca

Aequus Pharmaceuticals Inc. , a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation.

CEO: Douglas Glen Janzen
IPO: 2015
Employees: 12
HQ: Vancouver, BC, CA

Price Chart

-66.67% · this period

Valuation

Market Cap: $663.17K
P/E: -1.01
P/S: 0.72
P/B: -0.10
EV/EBITDA: -24.20
Div Yield: 0.00%

Profitability

Gross Margin: 53.35%
Op Margin: -62.50%
Net Margin: -71.46%
ROE: 9.47%
ROIC: 66.39%

Growth & Income

Revenue: $584.24K · 129.21%
Net Income: $-2,177,662 · 26.55%
EPS: $-0.02 · 26.79%
Op Income: $-2,127,199
FCF YoY: 27.81%

Performance & Tape

52W High: $0.04
52W Low: $0.01
50D MA: $0.01
200D MA: $0.01
Beta: -0.29
Avg Volume: 74.17K

Get TickerSpark's AI analysis on AQS.V

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime